| 证券代码：301188 | 证券简称：力诺药包 公告编号：2025-036 | | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | 山东力诺医药包装股份有限公司 关于作废 2022 年及 2024 年限制性股票激励计划 部分已授予尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开第四届董事会第十次会议和第四届监事会第九次会议，审议通过了《关于作 废 2022 年及 2024 年限制性股票激励计划部分已授予尚未归属的限制性股票的 议案》，现将有关事项说明如下： 4、2022 年 4 月 25 日，公司召开第三届董事会第八次会议与第三届监事会 第八次会议，审议通过了《关于向激励对象首次授予限制性股票的议案》。公司 独立董事对该议案发表了独立意见。 5、2023 年 3 月 14 日，公司召开第三届董事会第十五次会议与第三届监事 会第十四次会议，审议通过了《关于向激励对象授予预留限制性股票的议案》。 公司独立董事对该议 ...

| 证券代码：301188 | 证券简称：力诺药包 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：123221 | 债券简称：力诺转债 | | 山东力诺医药包装股份有限公司 关于提请股东大会授权董事会办理以简易程序向特定对象发行股 票相关事宜的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第 四届董事会第十次会议，审议并通过《关于提请股东大会授权董事会办理以简易程序向 特定对象发行股票相关事宜的议案》，现将相关事宜公告如下。 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规及《公司章 程》的有关规定，拟提请公司股东大会授权公司董事会全权办理以简易程序向特定对象 发行融资总额不超过人民币三亿元且不超过最近一年末净资产百分之二十的股票（以下 简称"本次发行"）的相关事宜，授权有效期为 2024 年年度股东大会通过之日起至 2025 年年度股东大会召开之日止。本议案尚需提交公司股东大会审议，现将有关情况公告如 下： ...

民生证券股份有限公司 关于山东力诺医药包装股份有限公司 2024 年度跟踪报告 | 保荐机构名称：民生证券股份有限公司 | 被保荐公司简称：力诺药包 | | --- | --- | | 保荐代表人姓名：杨桂清 | 联系电话：0531-82596870 | | 保荐代表人姓名：任耀宗 | 联系电话：0531-82596870 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、上市公司信息披露审阅情况 | | | （1）是否及时审阅上市公司信息披 | 是 | | 露文件 | | | （2）未及时审阅上市公司信息披露 | 无 | | 文件的次数 | | | 2、督导上市公司建立健全并有效执 | | | 行规章制度的情况 | | | （1）是否督导上市公司建立健全规 章制度（包括但不限于防止关联方占 | | | 用公司资源的制度、募集资金管理制 | 是 | | 度、内控制度、内部审计制度、关联 | | | 交易制度） | | | （2）上市公司是否有效执行相关规 | 是 | | 章制度 | | | 3、募集资金监督情况 | | | （1）查询上市公司募集资金专户次 | 每月一次 | ...

民生证券股份有限公司 关于山东力诺医药包装股份有限公司 首次公开发行股票并在创业板上市之 保荐总结报告书 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为山东 力诺医药包装股份有限公司（以下简称"力诺药包"、"发行人"或"公司"）首 次公开发行股票并在创业板上市的保荐机构，负责力诺药包上市后的持续督导工 作，持续督导期至 2024 年 12 月 31 日届满。根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等有关规定，民生证券出具本保荐总结报告书。 一、保荐机构及保荐代表人承诺 （一）保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误 导性陈述或重大遗漏，本保荐机构及保荐代表人对其真实性、准确性、完整性承 担法律责任。 （二）本保荐机构及本人自愿接受中国证券监督管理委员会（以下简称"中 国证监会"）对保荐总结报告书相关事项进行的任何质询和调查。 （三）本保荐机构及本人自愿接受中国证监会按照《证券发行上市保荐业务 管理办法》 ...

目 录 | 一、内部控制审计报告…………………………………………第 | | 1—2 | 页 | | --- | --- | --- | --- | | 二、附件 ……………………………………………………… | 第 | 3—6 | 页 | | （一）本所执业证书复印件 ……………………………………第 | | 3 | 页 | | （二）本所营业执照复印件 ……………………………………第 | | 4 | 页 | | （三）注册会计师证书复印件 ……………………………… | 第 | 5-6 | 页 | 内部控制审计报告 天健审〔2025〕4-358 号 山东力诺医药包装股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了山东力诺医药包装股份有限公司（以下简称力诺药包公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是力诺 药包公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基 ...

北京市中伦律师事务所 关于山东力诺医药包装股份有限公司 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦律师事务所 关于山东力诺医药包装股份有限公司 2022 年限制性股票激励计划、2024 年限制性股票 激励计划 部分限制性股票作废事项的 法律意见书 二〇二五年四月 2022 年限制性股票激励计划、2024 年限制性股票激励计划 部分限制性股票作废事项的 法律意见书 致：山东力诺医药包装股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受山东力诺医药包装股份有 限公司（以 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,080,841,711.81, representing a 14.09% increase compared to ¥947,367,565.13 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥66,067,595.87, a slight increase of 0.23% from ¥65,917,716.81 in 2023[22]. - The net cash flow from operating activities significantly improved to ¥123,008,248.62, up 100.37% from ¥61,390,824.54 in 2023[22]. - The total assets at the end of 2024 were ¥2,356,016,894.42, reflecting a 9.54% increase from ¥2,150,922,078.33 at the end of 2023[22]. - The company reported a basic earnings per share of ¥0.29 for 2024, a 3.57% increase from ¥0.28 in 2023[22]. - The company's revenue reached a historical high of 1.081 billion yuan, representing a year-on-year growth of 14.09%[42]. - The net profit attributable to shareholders was 66.07 million yuan, remaining stable compared to the previous year[42]. - The sales revenue from the pharmaceutical glass business was 467 million yuan, with a year-on-year increase of 15.02%[43]. - The sales of borosilicate pharmaceutical glass bottles reached 390 million yuan, marking a growth rate of 17.82%[43]. Dividend Distribution - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the dividend record date for the 2024 fiscal year[5]. - The cash dividend amount represents 100% of the total profit distribution, with a distributable profit of 385,511,446.00 RMB[185]. - The total number of shares eligible for the cash dividend distribution is 228,925,589 shares, with no stock bonus or capital reserve conversion planned[185]. - The cash dividend distribution process has been transparent and allows minority shareholders to express their opinions[183]. - The company has established a complete decision-making process for its cash dividend policy[183]. Research and Development - The company's R&D investment for 2024 reached 33.7971 million yuan, an increase of 12.16% compared to 2023, focusing on product development and process upgrades[47]. - The company holds 133 patents, an increase of 20 patents compared to the end of the previous year[47]. - The company is investing in R&D, allocating 100 million RMB for the development of new technologies in the pharmaceutical sector[158]. - The company is focusing on enhancing its R&D capabilities by enhancing core technologies and developing high-value-added products, while also improving automation levels and increasing per capita output[103]. Market and Competition - The pharmaceutical packaging sector saw increased competition with new entrants and expanded production, leading to a decrease in prices for borosilicate glass products[33]. - The relationship between pharmaceutical companies and packaging firms has strengthened, providing the company with opportunities for rapid growth[33]. - The company has maintained a leading position in the pharmaceutical packaging industry, which is advantageous for leveraging its strengths[33]. - The global pharmaceutical packaging market reached a sales figure of 472.54 billion yuan in 2023, with a projected CAGR of 3.85% from 2023 to 2030[34]. - The domestic pharmaceutical glass market size was 35 billion yuan in 2023, expected to grow to 44.2 billion yuan by 2026, reflecting a CAGR of 8.51% from 2023 to 2026[34]. Strategic Initiatives - The company is focusing on digital transformation and has partnered with Siemens for smart manufacturing initiatives[45]. - The company has signed investment agreements to expand its international presence, including acquiring a 51% stake in The European Ampoules Company[46]. - The company aims to enhance its market presence through strategic acquisitions and partnerships in the pharmaceutical packaging sector[92]. - The company plans to enhance its overseas presence and has conducted market research in regions such as the Middle East, Southeast Asia, and Latin America[101]. - The company intends to pursue external mergers and acquisitions to integrate resources and overcome growth bottlenecks in 2025[101]. Governance and Management - The company has established a dedicated information disclosure system, ensuring timely and accurate communication with investors[125]. - The company’s governance practices align with legal and regulatory standards, with no significant discrepancies identified[127]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[128]. - The management team is stable, with no personnel sharing or interference from controlling shareholders, ensuring independent decision-making[130][131]. - The company has a strong management team with diverse backgrounds in engineering, law, and finance, enhancing its strategic capabilities[142][146][148]. Risk Management - The company has outlined potential risks and corresponding countermeasures in the section discussing future development prospects[5]. - The company is facing risks from intensified market competition, particularly in the pharmaceutical glass sector, and is committed to enhancing its core competitiveness to mitigate these risks[105]. - The company is actively managing investment project risks by forming stable supply relationships with key customers and closely monitoring project implementation quality and progress[109]. - The company is exposed to foreign exchange risks due to imports of raw materials and exports of products, and is taking measures to mitigate these risks through flexible foreign exchange hedging tools[110]. Employee Management - The total number of employees at the end of the reporting period is 1,446, with 935 in the parent company and 511 in major subsidiaries[176]. - The employee composition includes 1,075 production personnel, 101 sales personnel, 150 technical personnel, 13 financial personnel, and 107 administrative personnel[176]. - The company has implemented a performance-based salary system, combining job-based pay with performance evaluations[178]. - The company is enhancing its employee training programs, focusing on vocational skills and high-level talent development for 2025[179]. Financial Management - The company has a structured approach to financial management, with Li Guo as the financial director since December 2022[155]. - The total pre-tax compensation for the board members amounts to 530.05 million[164]. - The chairman, Yang Zhongchen, received a total compensation of 123.55 million[164]. - The general manager, Sun Pengfei, received a total compensation of 59.99 million[164]. Internal Control - The internal control system has been updated and improved according to the basic norms of enterprise internal control, effectively preventing operational risks[195]. - The company reported no significant internal control deficiencies during the reporting period, maintaining a robust internal control environment[198]. - The internal control audit report received a standard unqualified opinion[200]. - The company’s management has implemented measures to address any issues encountered during the integration of subsidiaries[196].

Financial Performance - The company's revenue for Q1 2025 was ¥275,983,006.27, representing a 3.38% increase compared to ¥266,965,666.19 in the same period last year[5] - Net profit attributable to shareholders increased by 63.36% to ¥40,523,819.58 from ¥24,806,349.19 year-on-year[5] - The net profit after deducting non-recurring gains and losses rose by 67.51% to ¥37,075,339.00 compared to ¥22,133,403.48 in the previous year[5] - The basic earnings per share increased by 54.55% to ¥0.17 from ¥0.11 in the same period last year[5] - Total operating revenue for Q1 2025 reached ¥275,983,006.27, an increase of 3.8% compared to ¥266,965,666.19 in the same period last year[21] - Net profit for the period was ¥40,523,819.58, representing a significant increase of 63.5% from ¥24,806,349.19 in the previous year[22] - Earnings per share (EPS) for the current period was ¥0.17, up from ¥0.11 in the same quarter last year, reflecting a 54.5% increase[22] Assets and Liabilities - Total assets at the end of Q1 2025 reached ¥2,441,589,870.02, a 3.63% increase from ¥2,356,016,894.42 at the end of the previous year[5] - Total assets increased to ¥2,441,589,870.02, up from ¥2,356,016,894.42, marking a growth of 3.6%[20] - Total liabilities rose to ¥865,613,498.97, compared to ¥801,801,927.49, indicating an increase of 8.0%[20] - The company's total equity attributable to shareholders reached ¥1,575,976,371.05, up from ¥1,554,214,966.93, a growth of 1.4%[20] Cash Flow - The net cash flow from operating activities improved by 48.71%, with a net outflow of ¥15,298,274.11 compared to ¥29,826,157.29 in the same period last year[11] - Operating cash flow net amount was -$15.3 million, an improvement from -$29.8 million in the previous period, indicating a reduction in cash outflow[24] - Net cash flow from financing activities was $11.3 million, a turnaround from -$45.6 million in the previous period, showing improved financing conditions[25] - The total cash and cash equivalents at the end of the period increased to $587.3 million, compared to $358.9 million at the end of the previous period[25] Investments and Expenses - The company experienced a significant increase in investment cash flow, with a net inflow of ¥187,926,983.77, up 507.19% from ¥30,950,279.05 in the previous year[11] - Research and development expenses increased to ¥7,289,160.27, compared to ¥6,973,816.66 in the previous year, reflecting a focus on innovation[21] - Cash paid for purchasing goods and services was $120.1 million, down from $148.7 million in the previous period, reflecting cost control measures[24] - Cash paid for other operating activities increased to $22.0 million from $12.2 million in the previous period, indicating higher operational expenses[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,487[13] - The company has a strong shareholder base, with the largest shareholder, Linuo Investment Holding Group, holding 33.08% of shares[15] Future Outlook - The company is exploring new product development and market expansion strategies to enhance growth potential[15] - Future guidance indicates a focus on increasing operational efficiency and expanding market presence in the renewable energy sector[15] - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its market position[15]

山东力诺医药包装股份有限公司 独立董事2024年度述职报告 （杨公随） 各位股东及股东代表： （一）工作履历及专业背景 本人杨公随，中国国籍，出生于 1966 年，无境外永久居留权，博士研究生， 会计学教授、注册会计师。1988 年 7 月至 2004 年 8 月，任教于山东经济学院， 历任会计系讲师、会计学院副教授；2004 年 9 月至 2005 年 6 月，任清华大学访 问学者；2005 年 9 月至 2008 年 6 月，河海大学攻读博士学位；2008 年 7 月至今 任山东财经大学会计学教授。2020 年 10 月至今，任山东三元生物科技股份有限 公司独立董事；2018 年 12 月至今任山东新石基教育科技有限公司监事；2022 年 12 月至今任山东弘宇精机股份有限公司独立董事。2024 年 4 月起任公司独立董 事。 （二）不存在影响独立性的情况 本人未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在妨碍本人进行独立客观判断的关系， 不存在影响独立董事独立性的情况，符合《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 2 ...

（一）工作履历及专业背景 山东力诺医药包装股份有限公司 本人刘媛，中国国籍，无境外永久居留权，硕士研究生。2004 年 10 月至 2007 年 5 月历任山东泺源律师事务所律师助理、律师；2007 年 6 月至今任北京德恒 （济南）律师事务所高级合伙人、并购与公司证券专委会副主任。2024 年 4 月 起任公司独立董事。 （二）不存在影响独立性的情况 独立董事2024年度述职报告 本人作为山东力诺医药包装股份有限公司（以下简称"公司"）的第四届独立 董事，在任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》《公司章程》等相关法律、法规、规章的规定和 要求，在 2024 年度工作中，依据独立、客观、公正的原则，诚实、勤勉地履行 独立董事职责，积极出席相关会议，认真审议董事会各项议案，充分发挥了独立 董事及各专门委员会的作用，促进公司规范运作，维护公司整体利益，维护全体 股东尤其是中小股东的合法权益。现就本人 2024 年度履行独立董事职责情况汇 报如下： 一、独立董事基本情况： （刘媛） 各 ...